LGD-6972 sodium | CAS#1207989-22-7 | glucagon receptor antagonist

MedKoo Cat#: 598784 | Name: LGD-6972 sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

LGD-6972 sodium is a glucagon receptor antagonist.

Chemical Structure

LGD-6972 sodium

CAS#1207989-22-7 (sodium)

Theoretical Analysis

MedKoo Cat#: 598784

Name: LGD-6972 sodium

CAS#: 1207989-22-7 (sodium)

Chemical Formula: C43H45N2NaO5S

Exact Mass: 0.0000

Molecular Weight: 724.89

Elemental Analysis: C, 71.25; H, 6.26; N, 3.86; Na, 3.17; O, 11.04; S, 4.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

1207989-09-0 (free) 1207989-22-7 (sodium) LGD 6972 (ammonium salt)

Synonym

LGD-6972 sodium; LGD 6972 sodium; LGD6972 sodium;

IUPAC/Chemical Name

sodium (R)-2-(4-(2-(4'-(tert-butyl)-[1,1'-biphenyl]-4-yl)-3-oxo-3-((2',4',6'-trimethyl-[1,1'-biphenyl]-4-yl)amino)propyl)benzamido)ethane-1-sulfonate

InChi Key

UXVQTOIZZKLZCS-DRRLCDGFSA-M

InChi Code

InChI=1S/C43H46N2O5S.Na/c1-28-25-29(2)40(30(3)26-28)35-17-21-38(22-18-35)45-42(47)39(27-31-7-9-36(10-8-31)41(46)44-23-24-51(48,49)50)34-13-11-32(12-14-34)33-15-19-37(20-16-33)43(4,5)6;/h7-22,25-26,39H,23-24,27H2,1-6H3,(H,44,46)(H,45,47)(H,48,49,50);/q;+1/p-1/t39-;/m1./s1

SMILES Code

O=C(NCCS(=O)([O-])=O)C1=CC=C(C[C@H](C2=CC=C(C3=CC=C(C(C)(C)C)C=C3)C=C2)C(NC4=CC=C(C5=C(C)C=C(C)C=C5C)C=C4)=O)C=C1.[Na+]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

LGD-6972 sodium is a glucagon receptor antagonist.

In vitro activity:

TBD

In vivo activity:

Herein this study reports that treatment with the novel, potent GRA, LGD-6972, results in dose-related decreases from baseline in FPG in subjects with T2DM. Glucose reduction was observed in fasting and postprandial states. The effects on glycaemia in T2DM subjects were accompanied by dose-related increases from baseline in fasting glucagon, total GLP-1 and active GLP-1. Reference: Diabetes Obes Metab. 2017 Jan;19(1):24-32. https://pubmed.ncbi.nlm.nih.gov/27501510/

Preparing Stock Solutions

The following data is based on the product molecular weight 724.89 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Vajda EG, Logan D, Lasseter K, Armas D, Plotkin DJ, Pipkin JD, Li YX, Zhou R, Klein D, Wei X, Dilzer S, Zhi L, Marschke KB. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jan;19(1):24-32. doi: 10.1111/dom.12752. Epub 2016 Aug 31. PMID: 27501510; PMCID: PMC5215471.

In vitro protocol:

TBD

In vivo protocol:

1: Vajda EG, Logan D, Lasseter K, Armas D, Plotkin DJ, Pipkin JD, Li YX, Zhou R, Klein D, Wei X, Dilzer S, Zhi L, Marschke KB. Pharmacokinetics and pharmacodynamics of single and multiple doses of the glucagon receptor antagonist LGD-6972 in healthy subjects and subjects with type 2 diabetes mellitus. Diabetes Obes Metab. 2017 Jan;19(1):24-32. doi: 10.1111/dom.12752. Epub 2016 Aug 31. PubMed PMID: 27501510; PubMed Central PMCID: PMC5215471.